High mortality among tuberculosis patients on treatment in Nigeria: a retrospective cohort study

被引:48
作者
Adamu, Aishatu L. [1 ,2 ]
Gadanya, Muktar A. [1 ,2 ]
Abubakar, Isa S. [1 ,2 ]
Jibo, Abubakar M. [1 ,2 ]
Bello, Musa M. [1 ,2 ]
Gajida, Auwalu U. [1 ,2 ]
Babashani, Musa M. [3 ,4 ]
Abubakar, Ibrahim [5 ]
机构
[1] Bayero Univ Kano, Coll Hlth Sci, Dept Community Med, Kano, Nigeria
[2] Aminu Kano Teaching Hosp, Dept Community Med, Kano, Nigeria
[3] Bayero Univ Kano, Coll Hlth Sci, Dept Med, Kano, Nigeria
[4] Aminu Kano Teaching Hosp, Dept Med, Kano, Nigeria
[5] UCL, Inst Global Hlth, London, England
基金
英国医学研究理事会;
关键词
Tuberculosis; Mortality; Risk factors; Adults; Nigeria; Retrospective cohort; PULMONARY TUBERCULOSIS; RISK-FACTORS; TREATMENT OUTCOMES; DIAGNOSTIC DELAY; DRUG-RESISTANCE; HIV; DEATH; TB; OPPORTUNITIES; TRANSMISSION;
D O I
10.1186/s12879-017-2249-4
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Background: Tuberculosis (TB) remains a leading cause of death in much of sub-Saharan Africa despite available effective treatment. Prompt initiation of TB treatment and access to antiretroviral therapy (ART) remains vital to the success of TB control. We assessed time to mortality after treatment onset using data from a large treatment centre in Nigeria. Methods: We analysed a retrospective cohort of TB patients that commenced treatment between January 2010 and December 2014 in Aminu Kano Teaching Hospital. We estimated mortality rates per person-months at risk (pm). Cox proportional hazards model was used to determine risk factors for mortality. Results: Among 1,424 patients with a median age of 36.6 years, 237 patients (16.6%) died after commencing TB treatment giving a mortality rate of 3.68 per 100 pm of treatment in this cohort. Most deaths occurred soon after treatment onset with a mortality rate of 37.6 per 100 pm in the 1(st) week of treatment. Risk factors for death were being HIV-positive but not on anti-retroviral treatment (ART) (aHR 1.39(1 . 04-1 . 85)), residence outside the city (aHR 3 . 18(2.28-4.45)), previous TB treatment (aHR 3.48(2.54-4.77)), no microbiological confirmation (aHR 4.96(2.69-9.17)), having both pulmonary and extra-pulmonary TB (aHR 1.45(1.03-2.02), and referral from a non-programme linked clinic/centre (aHR 3.02(2.01-4.53)). Conclusions: We attribute early deaths in this relatively young cohort to delay in diagnosis and treatment of TB, inadequate treatment of drug-resistant TB, and poor ART access. Considerable expansion and improvement in quality of diagnosis and treatment services for TB and HIV are needed to achieve the sustainable development goal of reducing TB deaths by 95% by 2035.
引用
收藏
页数:11
相关论文
共 73 条
[1]   Uniting to end the TB epidemic: advances in disease control from prevention to better diagnosis and treatment [J].
Abubakar, Ibrahim ;
Lipman, Marc ;
McHugh, Timothy D. ;
Fletcher, Helen .
BMC MEDICINE, 2016, 14
[2]  
Adamu A. U., 2015, The Journal of American Science, V11, P293
[3]   Risk factors of treatment default and death among tuberculosis patients in a resource-limited setting [J].
Alobu, Isaac ;
Oshi, Sarah N. ;
Oshi, Daniel C. ;
Ukwaja, Kingsley N. .
ASIAN PACIFIC JOURNAL OF TROPICAL MEDICINE, 2014, 7 (12) :977-984
[4]  
Amoran OE., 2013, NIGER MED PRACT, V63, P74
[5]  
[Anonymous], 2015, GLOB AIDS RESP COUNT
[6]   Persistent High Mortality in Advanced HIV/TB Despite Appropriate Antiretroviral and Antitubercular Therapy: an Emerging Challenge [J].
Bisson, Gregory P. ;
Zetola, Nicola ;
Collman, Ronald G. .
CURRENT HIV/AIDS REPORTS, 2015, 12 (01) :107-116
[7]  
Cai J., 2015, PLoS ONE, V10, DOI [DOI 10.1371/JOURNAL.PONE.0120088, 10.1371]
[8]   Causes of Death in HIV-infected Persons Who Have Tuberculosis, Thailand [J].
Cain, Kevin P. ;
Anekthananon, Thanomsak ;
Burapat, Channawong ;
Akksilp, Sornsalk ;
Mankhatitham, Wiroj ;
Srinalk, Chawin ;
Nateniyom, Sriprapa ;
Sattayawuthipong, Wanchai ;
Tasaneeyapan, Theerawit ;
Varma, Jay K. .
EMERGING INFECTIOUS DISEASES, 2009, 15 (02) :258-264
[9]   Tuberculosis in sub-Saharan Africa: opportunities, challenges, and change in the era of antiretroviral treatment [J].
Corbett, EL ;
Marston, B ;
Churchyard, GJ ;
De Cock, KM .
LANCET, 2006, 367 (9514) :926-937
[10]  
Dauda M. M., 2010, Reviews in Infection, V1, P218